IDO1 and classic Hodgkin lymphoma: Using multiplex immunohistochemistry with tyramide signal amplification (TSA), Karihtala et al. [64] demonstrated that high proportions of PD-L1+ and IDO-1+ TAMs are both associated with unfavorable outcomes in cHL patients treated with standard chemotherapy.